Results 251 to 260 of about 354,322 (345)
CYTOGENETICS AND LONG-TERM SURVIVAL IN MM-003, A PHASE 3 TRIAL OF POMALIDOMIDE plus LOW-DOSE DEXAMETHASONE VS. HIGH-DOSE DEXAMETHASONE IN REFRACTORY OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA
, 2014 Meletios Α. Dimopoulos, Katja Weisel, Kevin Song, Michel Delforge, Lionel Karlin, Hartmut Goldschmidt, Philippe Moreau, A. Baños, Albert Oriol, Laurent Garderet, Michèle Cavo, Иванова, Adrían Alegre, Joaquín Martínez‐López, C. I Chen, A. Spencer, Stefan Knop, NJ Bahlis, C. Renner, Xiaoyan Yu, Kelvin Hong, Lars Sternås, Christian Jacques, Mohamed H. Zaki, Jesús F. San Miguel +24 moreopenalex +1 more sourceSupplementary Figure 2 from Dual Chimeric Antigen Receptor T Cells Targeting CD38 and SLAMF7 with Independent Signaling Demonstrate Preclinical Efficacy and Safety in Multiple Myeloma
Nathalie Roders, Cécilia Nakid-Cordero, Fabio Raineri, Maxime Fayon, Audrey Abecassis, Caroline Choisy, Elisabeth Nelson, Claire Maillard, David Garrick, Alexis Talbot, Jean‐Paul Fermand, Bertrand Arnulf, Jean-Christophe Bories +12 moreopenalex +1 more sourceAdhesion of Immunoglobulins to Band3 Promotes Increased Erythrocyte Sedimentation Rate in Multiple Myeloma
Cell Proliferation, EarlyView.Decreased sialic acid increases the adhesion of RBC membranes to immunoglobulins leading to an increased erythrocyte sedimentation rate (ESR). The increase in reactive oxygen species (ROS) damages the sialic acid glycosyl chains on the surface of RBC membrane proteins, causing the membrane proteins to be overexposed to the plasma environment due to the Sicheng Bian, Jiangxia Cui, Xialin Zhang, Chongzhi Bai, Yanhong Tan, Zhuanghui Hao, Xingpeng Bu, Changxin Qu, Lili Sun, Leilei Lin, Qi Wang, Zhengrui Li, Xufeng Huang, Hengrui Liu, Ruo Wang, Yinghua Li, Hongwei Wang +16 morewiley +1 more sourceRestoring sensitivity to daratumumab with all-transretinoic acid in a patient with daratumumab-refractory multiple myeloma: A case report and review of the literature
Current Problems in Cancer: Case ReportsNoa Biran, David H. Vesole, Harsh Parmar, Pooja Phull, Susan Kumka, Kimberley Doucette, Joshua Zenreich, Bianca DeAgresta, Alexandra Della Pia, Lisa Biamonte, Martha Campanaro, Trina McClendon, Samanta BaboolallAracena, Palka Anand, Adolfo Aleman, Monique Pace, Genevieve Breeze, Kristin Ivanovski, Marie Layton, David S. Siegel +19 moredoaj +1 more sourceB-Cell Maturation Antigen/CD19 Dual-Targeting Immunotherapy in Newly Diagnosed Multiple Myeloma [PDF]
Wanting Qiang, Jing Lu, Yanchun Jia, Jia Liu, Jin Liu, Haiyan He, Xiaoxiang Wang, Xiaoqiang Fan, Lina Jin, Qianqi Ruan, Qi Zhang, Lianjun Shen, Lihong Weng, Wei Cao, Wenling Li, Juan Du +15 moreopenalex +1 more sourceComparative Effectiveness and Safety of PI‐Rd Triplets in Relapsed/Refractory Multiple Myeloma: INSIGHT‐MM Data Analysis
European Journal of Haematology, EarlyView.Assessment of the comparative effectiveness and safety of three PI‐Rd triplets in relapsed/refractory multiple myeloma using data from the global, non‐interventional, observational INSIGHT‐MM study. ABSTRACT Objectives
To assess the effectiveness/safety of three proteasome inhibitors (PIs), plus lenalidomide‐dexamethasone (Rd) triplet regimens, for the Noemi Puig, Xavier Leleu, Hans C. Lee, Faith E. Davies, Roman Hájek, Vania Hungria, Michael A. Thompson, Gordon Cook, Jorge Vela Ojeda, Katja C. Weisel, Jesus G. Berdeja, Saad Z. Usmani, Argiris Symeonidis, Isabel Nascimento‐Ferreira, David Arthur, Lenka Mokrá, Kaili Ren, Dasha Cherepanov, Evangelos Terpos +18 morewiley +1 more source
